Related Experiment Videos
Pleural mesothelioma
1Institut Gustave Roussy, Villejuif, France.
Abstract:
Diffuse pleural malignant mesothelioma (DMM) is an uncommon tumor in the general population, but its incidence can be very high in persons exposed to asbestos. There has been controversy about the role of the different fiber types and their responsibility for causing DMM, particularly with chrysotile. Distinguishing between DMM and peripheral adenocarcinoma with pleural involvement is a frequent diagnostic problem. Immunohistochemical markers (positive for vimentin and negative for carcinoembryonic antigen and Leu M1) and electronmicroscopy aid in the diagnosis. Therapeutic results remain poor, and cure of DMM is rare. Local treatments such as surgery or radiation therapy are technically difficult because of the extent of disease. DMM continues to be a chemoresistant tumor. Because DMM is rare, study of this tumor has been hampered by the limited number of available patients in any given institution. Therefore, animal models or representative human malignant mesothelioma cell lines are needed for a dual investigation: first of the basic biology of this disease and second for a preclinical evaluation of chemotherapeutic agents and recombinant anticancer cytokines alone or in combination. Ongoing trials confirm that DMM is resistant to standard forms of therapy, but mesothelial cells are susceptible to immune effector cells and cytokines in in vitro and in vivo models. Thus, recombinant interferon-alpha, -beta, and -gamma have been used for both local and systemic treatment, as has interleukin-2 with and without autologous lymphokine-activated killer cells. In addition, substantial experimental evidence suggests synergy between cytotoxic drugs and cytokines.
Insights
Diffuse pleural malignant mesothelioma (DMM) is a rare asbestos-related cancer. Research highlights challenges in diagnosis and poor treatment outcomes, emphasizing the need for new therapeutic strategies.
Area of Science:
- Oncology
- Pathology
- Asbestos-related diseases
Background:
- Diffuse pleural malignant mesothelioma (DMM) is a rare cancer, often linked to asbestos exposure.
- Distinguishing DMM from other pleural conditions like adenocarcinoma can be diagnostically challenging.
- Current therapeutic outcomes for DMM are generally poor, with limited curative options.
Purpose of the Study:
- To review the diagnostic challenges and therapeutic limitations of DMM.
- To highlight the need for improved diagnostic tools and treatment strategies for DMM.
- To explore the potential of novel therapies, including immunotherapy, for DMM.
Main Methods:
- Review of diagnostic markers including immunohistochemistry and electron microscopy.
- Analysis of treatment outcomes for DMM, including surgery, radiation, and chemotherapy.
- Exploration of preclinical data on immunotherapy agents like interferons and interleukins for DMM.
Main Results:
- Immunohistochemical markers and electron microscopy assist in differentiating DMM from adenocarcinoma.
- DMM is largely chemoresistant, and local treatments are often difficult due to disease extent.
- In vitro and in vivo models show mesothelial cells are sensitive to cytokines and immune cells, suggesting immunotherapy potential.
Conclusions:
- Improved diagnostic methods are crucial for timely DMM management.
- Novel therapeutic approaches, particularly immunotherapy and combination therapies, show promise for DMM.
- Further research using cell lines and animal models is essential for preclinical evaluation of new DMM treatments.